Rorer recombinant Factor VIII
Invitron will supply Rorer with the genetically derived antihemophilic product for early clinical trials. Invitron will also supply between one and two kilograms of monoclonal antibody in 1988 for purification of Rorer's Monoclate plasma-derived Factor VIII.
You may also be interested in...
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.
Congress should give FDA more flexibility to administer orphan designations, such as the ability to revoke designations later if the disease prevalence grows beyond the rare disease threshold.
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.